List of Excipients in Branded Drug TRIJARDY XR

« Back to Dashboard

Trijardy XR Excipient Strategy and Commercial Opportunities

Last updated: September 26, 2026

Trijardy XR combines empagliflozin, linagliptin, and extended-release metformin hydrochloride in a single oral tablet for adults with type 2 diabetes. Its commercial value comes from fixed-dose convenience and adherence potential, while its formulation complexity creates barriers for generic substitution.

The excipient strategy supports three technical requirements: immediate release of empagliflozin and linagliptin, prolonged release of metformin, and physical separation of chemically and dose-wise distinct drug components. The main commercial opportunities are generic development, alternative fixed-dose combinations, excipient-enabled lifecycle management, regional supply, and reformulations that reduce tablet burden or gastrointestinal intolerance.

What is Trijardy XR and how is it formulated?

Trijardy XR is a fixed-dose combination of:

Component	Pharmacologic role	Release profile
Empagliflozin	SGLT2 inhibitor	Immediate release
Linagliptin	DPP-4 inhibitor	Immediate release
Metformin hydrochloride	Biguanide	Extended release

The FDA-approved strengths are:

• Empagliflozin 5 mg / linagliptin 2.5 mg / metformin HCl 500 mg
• Empagliflozin 5 mg / linagliptin 2.5 mg / metformin HCl 1,000 mg
• Empagliflozin 10 mg / linagliptin 5 mg / metformin HCl 500 mg
• Empagliflozin 10 mg / linagliptin 5 mg / metformin HCl 1,000 mg
• Empagliflozin 25 mg / linagliptin 5 mg / metformin HCl 500 mg
• Empagliflozin 25 mg / linagliptin 5 mg / metformin HCl 1,000 mg

The product is marketed by Boehringer Ingelheim Pharmaceuticals and Eli Lilly under the Jardiance and Tradjenta franchises. FDA approved Trijardy XR in January 2020. The drug is indicated as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes already treated with empagliflozin, linagliptin, and metformin, or in patients inadequately controlled on these agents. [1]

What excipients are used in Trijardy XR?

The FDA prescribing information identifies a multipart tablet excipient system. The inactive ingredients include materials used for tablet formation, lubrication, film coating, and controlled release. The label identifies the following excipient classes and components:

Excipient or excipient class	Likely technical function
Copovidone or povidone-type binder	Granulation and mechanical strength
Microcrystalline cellulose	Diluent and compressibility aid
Colloidal silicon dioxide	Glidant and flow control
Magnesium stearate	Lubricant
Hypromellose	Matrix former or film-coating polymer
Polyethylene glycol	Plasticizer in film coating
Talc	Anti-tacking and coating aid
Titanium dioxide	Opacifier and pigment
Iron oxides	Color identification by strength

The precise excipient composition can vary by tablet layer and manufacturing stage. The FDA label should control for regulatory and formulation analysis because public product descriptions do not always distinguish core excipients from coating components. [1]

Why does Trijardy XR use a multipart release design?

Metformin is administered at a much higher mass than empagliflozin or linagliptin. The 500 mg and 1,000 mg metformin doses create a large tablet-load problem if the three ingredients are placed into a simple immediate-release blend.

An extended-release metformin matrix can address several formulation objectives:

1. Reduce the number of daily administrations.
2. Limit rapid metformin exposure.
3. Maintain a commercially practical tablet size.
4. Separate metformin release from the immediate-release delivery of empagliflozin and linagliptin.
5. Preserve dose flexibility across six strengths.

The excipient system therefore has a direct commercial function. It is not merely a low-cost tablet base. Polymer selection, granulation, compression force, coating weight, and dissolution control can affect bioequivalence and generic development risk.

What formulation patents protect Trijardy XR?

Trijardy XR is protected through a combination of product, formulation, method-of-use, and component-drug patent rights. The relevant intellectual-property structure is broader than the six-strength product label.

The principal patent categories are:

Patent category	Protected subject matter	Commercial relevance
Empagliflozin composition patents	Active pharmaceutical ingredient and related chemical matter	Foundational protection for Jardiance
Linagliptin composition patents	Active pharmaceutical ingredient and related salts or compounds	Foundational protection for Tradjenta
Metformin extended-release technology	Controlled-release delivery of metformin	Relevant to tablet design and dissolution
Fixed-dose combination patents	Empagliflozin, linagliptin, and metformin combinations	Directly relevant to Trijardy XR
Formulation patents	Layering, matrix systems, excipient ratios, and release profiles	Can delay non-infringing generic entry
Method-of-use patents	Treatment of type 2 diabetes and related patient populations	Potential Paragraph IV litigation asset
Manufacturing patents	Granulation, compression, coating, and process controls	Can restrict manufacturing approaches

The Orange Book status is dynamic because patents can be added, delisted, expire, or become subject to litigation. A complete commercial analysis must separate patents listed against Trijardy XR from patents listed against Jardiance, Tradjenta, and metformin products. FDA’s Orange Book is the controlling public source for listed patents and regulatory exclusivity. [2]

Trijardy XR does not have biosimilar exposure because it is a small-molecule oral drug, not a biologic. Competitive entry would occur through an abbreviated new drug application, not a biosimilar application.

When does Trijardy XR lose exclusivity?

Trijardy XR’s practical exclusivity timeline depends on several separate dates:

• FDA approval date: January 2020.
• New chemical entity exclusivity: generally not available for Trijardy XR because empagliflozin, linagliptin, and metformin were previously approved active ingredients.
• Fixed-combination or formulation exclusivity: potentially available if supported by the approved application and applicable statutory provisions.
• Patent expiry: depends on the specific patents listed in the Orange Book and any patent-term adjustment or extension.
• Paragraph IV litigation: can delay approval of a generic for up to 30 months after timely notice to the brand sponsor.
• Pediatric exclusivity: a six-month period may apply only if FDA grants it for qualifying studies.

A generic sponsor can seek approval before all listed patents expire by filing a Paragraph IV certification. The sponsor must assert that the patent is invalid, unenforceable, or will not be infringed. A first timely Paragraph IV filer may obtain 180-day generic exclusivity if statutory conditions are satisfied. [3]

There is no single “Trijardy XR exclusivity date” that determines market entry. The controlling date depends on the patent claim being challenged, the generic’s formulation, the certification strategy, and the outcome of litigation.

What generic entry risks exist for Trijardy XR?

Generic development risk is higher than for a conventional immediate-release single-ingredient tablet. A potential applicant must match:

• The active ingredients and strengths.
• The metformin extended-release profile.
• The immediate-release behavior of empagliflozin and linagliptin.
• Critical quality attributes across six strengths.
• Food-effect performance.
• Dissolution profiles in multiple media.
• Tablet dimensions, coating, hardness, and stability.
• Manufacturing consistency at commercial scale.

The largest technical risk is the release relationship between metformin and the two lower-dose immediate-release ingredients. A generic that achieves acceptable total exposure but produces a materially different release profile could face FDA review questions or additional bioequivalence work.

What makes the excipient system difficult to design around?

A competitor may avoid literal infringement by changing:

• The hydrophilic polymer used for metformin release.
• Granulation method.
• Tablet-layer architecture.
• Coating composition.
• Binder or lubricant concentration.
• Compression and coating process.
• Release-modifying excipient combination.

Those changes do not eliminate regulatory risk. The alternative formulation must still demonstrate bioequivalence and pharmaceutical equivalence. A design-around that changes excipients can create new dissolution, stability, or food-effect problems.

The most defensible brand position is usually a combination of patent claims and manufacturing know-how. Patents may claim the composition or release profile, while process knowledge protects scale-up conditions that are difficult to reproduce from the public label.

What commercial opportunities exist for Trijardy XR excipients?

Generic fixed-dose combinations

The largest opportunity is a generic Trijardy XR equivalent. Excipient suppliers can support applicants with:

• Direct-compression grades of microcrystalline cellulose.
• Controlled-viscosity hypromellose.
• Copovidone or povidone binders.
• Low-moisture excipient systems.
• High-purity magnesium stearate.
• Coating systems with matched color and opacity.
• Excipient premixes for process consistency.

The commercial opportunity is strongest for suppliers that can provide regulatory documentation, global compendial compliance, and multiple particle-size grades. A low-cost excipient without strong change-control support is less valuable in a complex fixed-dose product.

Reformulated metformin delivery

A reformulator could pursue a lower-burden or more tolerable metformin delivery system using:

• Hydrophilic matrix polymers.
• Multiparticulate beads.
• Osmotic delivery.
• Gastroretentive systems.
• Enteric or delayed-release approaches.
• Smaller tablets using higher drug-load excipients.

Any reformulation would need to preserve glycemic efficacy and address metformin’s gastrointestinal tolerability. FDA has separately evaluated delayed-release metformin products, showing that alternative release technologies can support product differentiation when pharmacokinetic and clinical claims are adequately supported. [4]

Regional fixed-dose products

Trijardy XR’s six-strength U.S. portfolio provides a template for regional combinations. Opportunities include products pairing:

• Empagliflozin with metformin.
• Linagliptin with metformin.
• An SGLT2 inhibitor with a DPP-4 inhibitor.
• An SGLT2 inhibitor with metformin in markets where linagliptin access is limited.

Local manufacturers may compete through lower-cost excipients, contract manufacturing, and country-specific regulatory pathways. Patent freedom to operate must be evaluated separately in each jurisdiction because composition, formulation, and method-of-use rights do not expire globally on the same date.

Patient-friendly dosage forms

Commercial alternatives could include:

• Smaller tablets.
• Twice-daily products with lower individual tablet mass.
• Sprinkle or multiparticulate formulations.
• Modified-release capsules.
• Combination packs with synchronized dosing.
• Packaging that improves adherence for older adults using multiple medicines.

The main limitation is metformin’s high dose. A smaller dosage form generally requires greater drug loading or a different delivery technology, both of which can affect manufacturability and tolerability.

How does Trijardy XR compare with competing diabetes combinations?

Product	Active ingredients	Main commercial distinction
Trijardy XR	Empagliflozin, linagliptin, metformin	Three-drug fixed-dose combination with extended-release metformin
Synjardy / Synjardy XR	Empagliflozin, metformin	Two-drug combination; lower formulation complexity
Glyxambi	Empagliflozin, linagliptin	Two-drug combination without metformin
Jentadueto / Jentadueto XR	Linagliptin, metformin	DPP-4 inhibitor plus metformin
Xigduo XR	Dapagliflozin, metformin	Competing SGLT2 inhibitor/metformin combination
Segluromet	Ertugliflozin, metformin	Alternative SGLT2 inhibitor/metformin product

Trijardy XR has a convenience advantage for patients already using all three therapies. Its disadvantage is formulation complexity and the possibility that a patient may need independent dose adjustment of one component. A two-drug combination can provide greater prescribing flexibility when the third agent is not clinically appropriate.

What is the FDA regulatory status and Orange Book position?

Trijardy XR is an FDA-approved prescription drug listed in the FDA’s Drugs@FDA database. The approval is an NDA for a fixed-dose combination product. FDA labeling includes contraindications, renal limitations, lactic acidosis warnings, ketoacidosis warnings, genital and urinary tract infection risks, pancreatitis-related warnings, and administration instructions for the extended-release tablet. [1]

The Orange Book is relevant for:

• Listed patents.
• Patent expiration dates.
• Regulatory exclusivity.
• Therapeutic equivalence determinations for approved generic products.
• Generic application competition.

An Orange Book listing does not guarantee that every listed patent will block every generic formulation. The scope depends on the patent claims and the proposed product’s composition, use, and manufacturing process.

Which companies are challenging Trijardy XR?

Publicly disclosed generic challenge activity must be assessed through FDA filings, Paragraph IV notices, patent complaints, and district-court docket records. No biosimilar competitor can challenge Trijardy XR because the product is not biologic.

The likely competitive groups are:

• Large generic manufacturers with experience in complex oral dosage forms.
• Companies that already market generic metformin extended-release products.
• SGLT2 inhibitor developers seeking fixed-dose combinations.
• Contract development and manufacturing organizations with multilayer-tablet capabilities.
• Regional manufacturers pursuing national approvals outside the United States.

A company may challenge only selected strengths or pursue a narrower product rather than replicate the full six-strength portfolio. The 1,000 mg metformin strengths are likely to receive the greatest attention because they address the highest-volume metformin dosing need.

What revenue exposure does Trijardy XR create?

Boehringer Ingelheim and Eli Lilly do not generally report Trijardy XR revenue as a separately disclosed product line in their public financial reporting. Revenue exposure is therefore better assessed through the broader Jardiance and diabetes portfolios than through a standalone Trijardy XR figure.

Commercial exposure has three layers:

1. Direct Trijardy XR sales.
2. Cannibalization of separate Jardiance, Tradjenta, and metformin prescriptions.
3. Portfolio defense against competing SGLT2 and DPP-4 combinations.

A generic Trijardy XR launch could pressure the fixed-dose product directly while also affecting demand for the branded components. The impact would depend on substitution rules, payer formulary placement, relative discounts, and whether physicians continue prescribing separate branded agents.

How strong is the Trijardy XR patent estate?

The estate is strongest where formulation and combination claims overlap with difficult bioequivalence requirements. It is weaker if protection depends mainly on broad treatment claims covering already known uses of empagliflozin, linagliptin, or metformin.

Strength factor	Assessment
Product complexity	High
Number of active ingredients	Three
Generic bioequivalence burden	High
Tablet-strength portfolio	Broad
Biosimilar risk	None
Formulation design-around potential	Moderate
Dependence on component patents	Significant
Manufacturing know-how value	High
Litigation uncertainty	Dependent on current Orange Book listings and claims

A generic applicant can potentially design around a formulation patent, but it cannot independently avoid unexpired composition or method patents if its proposed product falls within their claims. The commercial barrier is therefore cumulative rather than tied to a single excipient.

Key Takeaways

• Trijardy XR combines immediate-release empagliflozin and linagliptin with extended-release metformin.
• Its excipient strategy must manage a high-dose metformin matrix while preserving rapid release of the two lower-dose agents.
• The main excipient opportunities are controlled-release polymers, direct-compression excipients, coating systems, and regulatory-grade premixes.
• Generic development is technically more difficult than development of a single-ingredient immediate-release tablet.
• Trijardy XR has no biosimilar exposure because it is a small-molecule product.
• Paragraph IV challenges, Orange Book patents, and component-drug patent rights determine practical generic-entry risk.
• Revenue is not normally disclosed separately for Trijardy XR, so exposure must be assessed within the broader Jardiance and diabetes portfolios.
• The most valuable formulation know-how likely concerns release control, scale-up, dissolution, and manufacturing reproducibility.

FAQs

Can Trijardy XR excipients be replaced in a generic product?

Yes. A generic manufacturer can use different inactive ingredients if the product meets pharmaceutical equivalence, bioequivalence, quality, stability, and labeling requirements. The replacement excipients must not create a materially different release profile or safety issue.

Is Trijardy XR a multilayer tablet?

The product uses a formulation architecture designed to combine immediate-release and extended-release behavior. Public labeling does not provide enough manufacturing detail to establish every internal layer or processing step, so commercial analysis should rely on the FDA label and relevant patent claims rather than assuming a specific tablet architecture.

Which excipient is most important for Trijardy XR bioequivalence?

The release-controlling polymer system for metformin is likely the most important excipient variable. Its viscosity, particle properties, concentration, and processing conditions can affect dissolution and systemic exposure.

Can a company market generic empagliflozin-metformin without copying Trijardy XR?

Potentially. Empagliflozin-metformin is a different fixed-dose combination from Trijardy XR because it omits linagliptin. Regulatory approval and freedom to operate would depend on the applicable patents, formulation claims, and jurisdiction.

Does Trijardy XR have a pediatric exclusivity period?

FDA pediatric exclusivity is not established solely by the product’s approval date. Any applicable six-month pediatric extension must be confirmed through FDA exclusivity records and the relevant product-specific patent or exclusivity entries.

References

1. U.S. Food and Drug Administration. (2023). Trijardy XR (empagliflozin, linagliptin, and metformin hydrochloride extended-release tablets) prescribing information. Boehringer Ingelheim Pharmaceuticals, Inc.

2. U.S. Food and Drug Administration. (2024). Approved drug products with therapeutic equivalence evaluations: Orange Book. https://www.fda.gov/drugsatfda

3. U.S. Food and Drug Administration. (2024). ANDA submissions: Refuse-to-receive standards and Paragraph IV certification procedures. https://www.fda.gov/drugs

4. U.S. Food and Drug Administration. (2019). FDA approves first delayed-release metformin drug for type 2 diabetes. https://www.fda.gov/news-events/press-announcements